Alpha 2.0
Login Register
» Articles » PMID: 6624080

Treatment of Advanced Malignancy with Plasma Perfused over Staphylococcal Protein A

Overview
Journal West J Med
Specialty General Medicine
Date 1983 Jul 1
PMID 6624080
Citations 3
Authors
F R MacKintosh
K Bennett
S Schiff
J Shields
S W Hall
Affiliations
Soon will be listed here.
Abstract

A total of 14 extensively pretreated patients with advanced and progressive malignancy were given 140 infusions of autologous plasma that had been perfused over staphylococcal protein A bound to an agarose gel (Sepharose). Infusions ranged in volume from 35 ml to 260 ml (mean, 70 ml), and the quantity of protein A used ranged from 1 to 30 mg per 100 ml of plasma (mean, 10 mg). Acute toxic reactions included fever (21%), chills (18%), nausea (17%), vomiting (8%), pain (9%) and bronchospasm (2%). Four patients did not have an acute toxic reaction and no chronic or cumulative toxic effects were identified. In two patients there was objective tumor regression and in five there was stabilization of disease lasting from 4 to 12 weeks. Further study of this treatment modality is warranted.

Citing Articles

Correlation between surface morphology and surface forces of protein A adsorbed on mica.

Ohnishi S, Murata M, Hato M Biophys J. 1998; 74(1):455-65.

PMID: 9449346 PMC: 1299398. DOI: 10.1016/S0006-3495(98)77803-8.

Complexes prepared from protein A and human serum, IgG, or Fc gamma fragments: characterization by immunochemical analysis of ultracentrifugation fractions and studies on their interconversion.

Langone J, Das C, MAINWARING R, Shearer W Mol Cell Biochem. 1985; 65(2):159-70.

PMID: 3157047 DOI: 10.1007/BF00221099.

Mechanism of activation of human basophils by Staphylococcus aureus Cowan 1.

Marone G, Tamburini M, Giudizi M, Biagiotti R, Almerigogna F, Romagnani S Infect Immun. 1987; 55(3):803-9.

PMID: 2434428 PMC: 260413. DOI: 10.1128/iai.55.3.803-809.1987.

References
1.
Baldwin R, Price M, Robins R . Blocking of lymphocyte-mediated cytotoxicity for rat hepatoma cells by tumour-specific antigen-antibody complexes. Nat New Biol. 1972; 238(84):185-6. DOI: 10.1038/newbio238185a0. View
2.
Hellstrom K, Hellstrom I . Lymphocyte-mediated cytotoxicity and blocking serum activity to tumor antigens. Adv Immunol. 1974; 18:209-77. DOI: 10.1016/s0065-2776(08)60311-9. View
3.
Tamerius J, Nepom J, Hellstrom I, Hellstrom K . Tumor-associated blocking factors: isolation from sera of tumor-bearing mice. J Immunol. 1976; 116(3):724-30. View
4.
Bansal S, Bansal B, Boland J . Blocking and unblocking serum factors in neoplasia. Curr Top Microbiol Immunol. 1976; 75:45-76. DOI: 10.1007/978-3-642-66530-1_2. View
5.
Israel L, Edelstein R, Mannoni P, Radot E, GREENSPAN E . Plasmapheresis in patients with disseminated cancer: clinical results and correlation with changes in serum protein. The concept of "nonspecific blocking factors". Cancer. 1977; 40(6):3146-54. DOI: 10.1002/1097-0142(197712)40:6<3146::aid-cncr2820400659>3.0.co;2-n. View